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Chronic inflammation has recently been proposed to be a key mediator linking obesity to a cluster of cardiometabolic disorders. 
Obese adipose tissue, infiltrated with activated macrophages and mast cells, is an important source of systemic inflammation, by
secreting dozens of the pro-inflammatory adipokines into the blood stream. One the other hand, adiponectin, an abundant adipokine
secreted predominantly from adipocytes, is markedly decreased in obesity and associated inflammatory diseases. Adiponectin 
exerts its anti-inflammatory actions in several target cells by inhibiting the production and activities of tumor necrosis factor-
alpha, preventing the activation of nuclear factor-kappa B, and inducing expression of anti-inflammatory cytokines. In animal
models, adiponectin treatment alleviates several obesity-associated inflammatory diseases, such as atherosclerosis, nonalcoholic
steatohepatitis, asthma and acute myocardial infarction. In humans, circulating levels of adiponectin are inversely correlated with 
several well-established markers of inflammation, including C-reactive protein and interleukin-6. Furthermore, anti-inflammatory
drugs, such as peroxisome proliferator-activated receptor-gamma agonists, can elevate plasma levels of adiponectin. While the 
majority of clinical and animal data support the role of adiponectin as an anti-inflammatory, anti-atheroscerotic and anti-diabetic 
adipokine, a number of recent studies have reported its pro-inflammatory actions in certain conditions. Here, we summarize the
pathophysiological roles of adiponectin in inflammation-related disorders, and discuss the potential mechanisms involved, also 
their implications in  adiponectin-targeted pharmacotherapy. Biomed Rev 2006, 17: 11-22.
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INTRODUCTION
Obesity is the most common risk factor for a cluster of inter-
related cardiometabolic diseases, including atherosclerosis, 
myocardial infarction, type 2 diabetes mellitus (T2DM), meta-
bolic syndrome and also nonalcoholic steatohepatitis (NASH). 
A growing body of evidence suggests that a low-grade sub-
clinical inflammation, characterized by a moderate elevation
of inflammatory biomarkers in the circulation, plays a key role
in linking obesity to its associated pathologies. Adipose tissue, 
which was traditionally thought to be an inert energy storage 
compartment, is now appreciated to be a important contributor 
of systemic inflammation in obese subjects (1). Recent studies
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on both humans and animal models have demonstrated a large 
quantity of macrophage infiltration in obese adipose tissue.
In obese states, enlarged adipocytes, together with the sur-
rounding macrophages, act in a synergistic manner to secrete 
a cluster of pro-inflammatory factors into the blood stream,
including adipokines (leptin and resistin), cytokines [tumor 
nerosis factor-alpha (TNF-α) and interleukin-6 (IL-6)], acute-
phase proteins (serum amyloid protein and α-glycoprotein), the 
chemokines macrophage chemoattractant protein-1 (MCP-1) 
and macrophage inflammatory protein-1alpha (MIP-1α) (2). 
These proinflammatory factors play a causative role in the
development of obesity-related cardiometabolic disorders by 
inducing insulin resistance, accelerating atherosclerosis and 
instigating inflammation in liver and other peripheral tissues.
On the other hand, anti-inflammatory adipokines, such as
IL-10 and adiponectin, can provide protection against these 
conditions. 
Adiponectin is an abundant serum protein secreted pre-
dominantly from adipocytes, accounting for ~0.01% of the 
total human plasma protein (3). Unlike the pro-inflammatory
factors produced from adipose tissue, adipocyte production 
and circulating concentration of adiponectin are markedly 
decreased in obesity and its related pathological conditions, 
such as T2DM, NASH and coronary heart disease. This adi-
pokine has emerged as a key mediator regulating the balance 
between adipose tissue and inflammation.Adiponectin directly
affects the inflammatory response by regulating production
and activities of many cytokines and modulating the inflam-
matory pathways. 
In this review, we summarize the recent research progresses 
in adiponectin biology and its implication in the adipophar-
macolgy of inflammation-related diseases.
OLIGOMERIZATION AND POSTTRANSLATIONAL 
MODIFICATIONS OF ADIPONECTIN
Adiponectin is a 30 kD protein consisting of a hyper-variable 
NH2-terminal domain, followed by a collageneous domain 
comprising of 22 Gly-X-Y repeats and a COOH-terminal 
C1q-like globular domain (4). So far, close homologs of adi-
ponectin have been cloned from human, mouse, rat, bovine, 
rhesus monkey, pig, dog, and chicken. The primary amino acid 
sequences of these adiponectin homologs are very conserved 
across different species, sharing over 80 % similarity.
In the circulation, adiponectin is present predominantly as 
three distinct oligomeric complexes (5,6). The monomeric 
form of adiponectin has never been detected in native condi-
tions. The basic building block of adiponectin is a tightly as-
sociated homotrimer, which is formed via hydrophobic interac-
tions within its globular domains. Two trimers self associate to 
form a disulfide-linked hexamer, which further assembles into
a bouquet-like higher molecular weight (HMW) multimeric 
complex that consists of 12-18 protomers (7). The assembly 
of hexameric and HMW forms of adiponectin depends on the 
formation of a disulfide bond mediated by an NH2-terminal 
conserved cysteine residue within the hyper-variable region. 
Substitution of this cysteine with either alanine or serine leads 
exclusively to trimer formation (7,8). Notably, adiponectin 
produced from different sources have different compositions 
of the oligomeric complexes. The full-length adiponectin 
expressed in mammalian cells can form all three oligomeric 
forms, a pattern reminiscent of those observed in the circulation 
(9,10). On the other hand, full-length adiponectin produced 
from Escherichia coli can form the trimeric and hexameric 
forms, but not the HMW species.
Adiponectin is modified at the posttranslational level during
its secretion from adipocytes (11). Several lysine and proline 
residues within the collagenous domain are hydroxylated. Hy-
droxylysine residues at position 68, 71, 80, and 104 are further 
modified by a glucosyl α(1-2)galactosyl group, as determined 
by nuclear magnetic resonance analysis (12). Notably, each 
of these four lysines and their surrounding consensus motif 
[GXKGE(D)] are highly conserved across all species of adi-
ponectin. These posttranslational modifications appear to be
important for the formation of the HMW oligomeric complex 
of adiponectin. Disruption of hydroxylation and glycosylation 
by substitution of the four conserved lysines with arginines 
selectively abrogated the intracellular assembly of the HMW 
oligomers in vitro as well as in vivo (9, 10). In addition, adipo-
nectin was reported to be a α2,8-linked disialic acid-containing 
glycoprotein (13), although the functional relevance of this 
posttranslational modification remains to be determined.
 Different oligomers of adiponectin possess distinct biologi-
cal activities. The trimeric adiponectin is the most potent form 
involved in the insulin-sensitizing actions in skeletal muscle 
(7). On the other hand, the HMW oligomeric complex of 
adiponectin is the major bioactive form responsible for inhibi-
tion of hepatic glucose production (8,10), and for protection 
of endothelial cells from apoptosis (14). It has recently been 
proposed that the oligomeric complex distribution, but not the 
absolute amount of total adiponectin, determines insulin sen-
sitivity (3). It is important to note that many pharmacological 
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studies have been using the globular domain of adiponectin. 
In vitro, this fragment can be produced by proteolytic cleav-
age of full-length with leukocyte elastase (15). Nevertheless, 
the physiological relevance of this finding remains to be
established. 
ANTAGONISTIC EFFECTS BETWEEN ADIPONECTIN AND 
TUMOR NECROSIS FACTOR-ALPHA
The anti-inflammatory function of adiponectin was first sug-
gested by the finding that this adipokine can suppress the
production of TNF-α in macrophages (16). Since then, many 
in vitro and in vivo studies have demonstrated the reciprocal 
regulation between adiponectin and TNF-α. In addition to 
macrophages, adiponectin can inhibit TNF-α production in 
adipocytes (17), cardiomyocytes (18), Kupffer cells (19), and 
lymphocytes (20). Ablation of the adiponectin gene in mice 
increases TNF-α expression in adipose tissue and elevates 
plasma TNF-α concentrations, whereas supplementation of 
adiponectin reverses these changes (21). On the other hand, 
TNF-α has been shown to suppress adiponectin expression in 
3T3-L1 adipocytes (22) as well as in concanavalin A-treated 
mice with acute liver inflammation (23) .
Adiponectin and TNF-α also oppose each other’s activities 
in many target tissues, such as regulation of insulin sensitivity 
in skeletal muscle, gluconeogenesis in hepatocytes and NF-
κB in endothelial cells (21,24). Tumor necrosis factor-α is the 
causative factor of insulin resistance and vascular dysfunctions 
while adiponectin possesses insulin-sensitizing and vasculo-
protective effects. Notably, despite the lack of homology at 
the primary amino acid sequence level, the three-dimensional 
structures are strikingly similar between TNF-α and globular 
adiponectin (25). Both TNF-α and globular adiponectin have 
a 10-β strand jellyroll folding topology and form bell-shaped 
homotrimeric oligomers. Each of the 10 β-strands of globular 
adiponectin can be superimposed with the β-strands of TNF-α. 
The relative positions and lengths of these β-strands are almost 
identical between these two proteins (25). It is currently un-
clear how these two proteins with a similar structure possess 
completely opposite functions. 
PROTECTIVE ACTIONS OF ADIPONECTIN AGAINST LIVER 
INFLAMMATION
Our laboratory first reported the beneficial effect of adiponectin
against chronic liver inflammation in animal models of alco-
holic steatohepatitis (ASH) and NASH, a pathological condi-
tion commonly observed in obese individuals and patients 
with T2DM (26). We found that chronic supplementation of 
adiponectin alleviated hepatomegaly and steatosis, and also 
inhibited inflammation and necrosis in both ethanol-fed mice
with ASH and genetic ob/ob obese mice with NASH. In both 
these animal models, the elevated TNF-α production in the 
liver tissue was markedly suppressed following adiponectin 
treatment. Consistent with our findings, a recent study by
Thakur et al (27) demonstrated that ethanol-induced elevation 
of TNF-α production in Kupffer cells was normalized fol-
lowing adiponectin treatment. Furthermore, adiponectin was 
also implicated in the protective action of dietary saturated 
fat against the development of alcoholic fatty liver disease in 
mice (28). In agreement with these animal data, epidemiologi-
cal studies have demonstrated an inverse correlation between 
plasma levels of adiponectin and serum alanine aminotrans-
ferase (ALT), a marker of liver injury (26). Furthermore, hy-
poadiponectinemia has been reported to be an independently 
associated with NASH, more severe hepatic steatosis and 
necroinflammation in several ethnic groups (29-31).
In addition to NASH and ASH, the anti-inflammatory ef-
fects of adiponectin have also been demonstrated in several 
other animal models with acute liver inflammation. Masaki 
et al (32) investigated the role of adiponectin in D-galactos-
amine/lipopolysaccharide (GalN/LPS)-induced liver injury 
using KK-Ay obese mice, and found that pretreatment with 
adiponectin ameliorated the GalN/LPS-induced elevation 
of serum asparate aminotransferase and ALT levels and the 
apoptotic and necrotic changes in hepatocytes, resulting in a 
marked reduction in lethality. In addition, adiponectin pretreat-
ment caused a significant reduction in the GalN/LPS-induced
increases in serum and hepatic TNF-α levels. These findings
were further confirmed by a more recent study showing that
GalN/LPS induces more severe liver injury and much higher 
serum levels of ALT and TNF-α, but significantly lower levels
of IL-10 in adiponectin knockout (KO) mice compared to wild 
type controls (33). Kamada et al  (34) reported that adiponectin 
KO mice were more susceptible to liver fibrosis induced by
carbon tetrachloride, while adenovirus-mediated overexpres-
sion of adiponectin prevented the development of this disease. 
Furthermore, administration of adiponectin has been shown to 
be protective in the model of liver damage induced by admin-
istration of concanavalin A, possibly by modulating production 
of IL-10 as well as TNF-α bioactivity (35). 
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ANTI-ATHEROSCLEROTIC EFFECTS OF ADIPONECTIN
Inflammation plays a central role in the pathogenesis of athero-
sclerosis (36). Chronic inflammatory processes and immune
mechanisms contribute to development of atherosclerosis at 
all stages, including activation of vascular endothelium, early 
lesion formation, lesion progression, as well as the onset of 
plaque rupture and thrombosis. Growing evidence suggests 
the protective effects of adiponectin against atherosclerosis are 
partly mediated by its anti-inflammatory properties. Adenovi-
rus-mediated overexpression of full-length adiponectin (37) 
and transgenic overexpression of globular adiponectin (38) 
have been shown to inhibit atherosclerotic lesion formation 
in the aortic sinus of apolipoprotein E deficient mice, a well
established animal model that can spontaneously develop ath-
erosclerosis. Notably, the reduction of atherosclerotic plaques 
by adiponectin was associated with decreased expression of 
adhesion molecules (such as vascular cell adhesion molecule-1 
and intracellular adhesion molecules-1) and TNF-α in aortic 
tissue (37). On the other hand, disruption of the adiponectin 
gene results in impaired vasoreactivity (39) and increased 
neointimal thickening in response to external vascular cuff 
injury (40,41). These animal data were also supported by 
several clinical reports showing an independent negative 
association between serum adiponectin levels and carotid 
intima-media thickness, the well-established marker of early 
atherosclerosis (42). 
Adiponectin has been shown to inhibit almost every step 
of atherosclerotic formation, including activation of endo-
thelial cells, monocyte attachments, foam cell formation and 
smooth muscle proliferation. In endothelial cells, adiponectin 
dose-dependently suppresses both TNF-α and resistin-induced 
production of pro-inflammatory adhesion molecules, such as
intracellular adhesion molecules-1, vascular cell adhesion 
molecule-1, and E-selectin, and the chemokine IL-8 (CXCL8) 
(43-46). These effects are primarily attributed to the ability 
of adiponectin to inhibit TNF-α-induced activation of the NF-
κB signaling pathway, which stimulates gene transcription of 
many adhesion molecules and cytokines. Therefore, suppres-
sion of NF-κB by adiponectin might represent a major cellular 
mechanism for inhibition of monocyte adhesion to endothelial 
cells, the first crucial step leading to atherosclerosis.
In macrophages, adiponectin prevents foam cell formation 
by inhibiting expression of class A scavenger receptors and 
uptake of acetylated low density lipoprotein particles (47). In 
addition, adiponectin decreases production of interferon-γ (48) 
and inhibits both leptin and LPS-induced TNF-α expression 
via suppression of the extracellular signal-regulated kinase 
(ERK) 1/2 and p38 mitogen activated protein kinase (MAPK) 
pathways (49,50), while it increases expression of the anti-
inflammatory cytokines IL-10 and IL-1 receptor antagonist
through the activation of phosphoinositide-3 kinase (51,52). 
Globular adiponectin inhibits toll-like receptor mediated 
activation of the NF-κB signaling pathway through its puta-
tive receptor adipoR1 (53). In addition, adiponectin has been 
shown to selectively induce the expression of tissue inhibi-
tor of metalloproteinase 1 (54), suggesting that adiponectin 
may have inhibitory effects on the rupture of atherosclerotic 
plaque lesions. 
In cultured aortic smooth muscle cells, adiponectin inhibits 
cell proliferation and migration induced by several atherogenic 
growth factors, including heparin-binding epidermal growth 
factor-like growth factor, platelet-derived growth factor BB, 
and basic fibroblast growth factor (55,56). Adiponectin oligo-
mers interact with these growth factors and subsequently block 
their binding to the respective cell membrane receptors.
CARDIAC PROTECTION BY ADIPONECTIN
Several recent animal studies have demonstrated the protec-
tive effects of adiponectin against both acute and chronic 
cardiac injuries (18,57,58). Ablation of the adiponectin gene 
in mice results in enhanced concentric cardiac hypertrophy, 
exacerbated heart failure and increased mortality in response 
to pressure overload (57,58). On the other hand, supplemen-
tation with adiponectin attenuates pressure overload-induced 
cardiac hypertrophy in both lean mice and db/db diabetic mice, 
suggesting that this adipokine might be a general suppressor 
of hypertrophic cardiomyopathy, a pathological condition 
closely associated with obesity and diabetes. In a more recent 
study, Shibata et al have shown that adiponectin-deficient mice
develop much larger infarcts than wild-type mice after acute 
ischemia–reperfusion (18). This change is associated with 
increased myocardial cell apoptosis and TNF-α expression 
in the adiponectin-deficient mice. On the other hand, treat-
ment with adiponectin diminishes infarct size, myocardial 
apoptosis and TNF-α production in both adiponectin-KO and 
wild-type mice. 
The protective effects of adiponectin against myocardial 
ischemia–reperfusion injury are mediated by its ability to 
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activate AMP-activated protein kinase (AMPK) and cyclo-
oxygenase-2 (COX-2) in cardiac cells (18). Overexpression 
of dominant-negative AMPK blocks the anti-apoptotic actions 
of adiponectin in cardiac myocytes, indicating that the pro-
survival effects of this protein are mediated primarily through 
AMPK-dependent pathway. On the other hand, the anti-inflam-
matory functions of adiponectin in cardiac cells are primarily 
attributed to its activation of the COX-2-dependent pathway 
(18). In cardiomyocytes, adiponectin enhances COX-2 activ-
ity, resulting in the increases in prostaglandin E2 synthesis and 
the inhibition of LPS-induced TNF-α production. Inhibition 
of COX-2 by its pharmacological inhibitors attenuates the 
suppressive effects of adiponectin on LPS-induced TNF-α 
production, and also partially reverses the protective actions 
of adiponectin on infarct size in mice. 
Consistent with these animal studies, several epidemio-
logical studies have demonstrated the close association of 
hypoadiponectinemia with coronary heart disease, independent 
of classical risk factors (59,60). In a large nested case-control 
study by Pischon et al (61), high plasma levels of adiponectin 
are found to be associated with a significantly decreased risk
of myocardiac infarction over a follow-up period of 6 years 
among 18,225 male participants without previous history 
of cardiovascular disease. Furthermore, adiponectin levels 
rapidly decline after acute myocardial infarction (62). The 
reduction of plasma adiponectin levels after acute myocardial 
infarction inversely correlates with plasma levels of C-reac-
tive protein (CRP), suggesting that hypoadiponectinemia is 
associated with an increased inflammatory response to acute
myocardial ischemia.
AUTOCRINE FUNCTIONS OF ADIPONECTIN
In addition to the suppression of TNF-α expression, adiponec-
tin can act in an autocrine manner to regulate the production 
of several other adipokines in adipocytes. A recent antibody 
array-based analysis showed that chronic treatment of human 
adipocytes with adiponectin downregulated the secretion of 
a cluster of pro-inflammatory factors, including IL-6, IL-
8, growth-regulated oncogene-α MCP-1 (CCL2), MIP-1α, 
MIP-1ß, and osteoprotegerin (63). This study also provided 
evidence suggesting that the insulin-sensitizing activity of 
adiponectin in skeletal muscle was mediated, at least in part, 
by its suppressive effects on secretion of these pro-inflamma-
tory factors. Another study in pig primary adipocytes showed 
that adiponectin suppressed LPS-induced activation of NF-κB 
and induction of IL-6 and TNF-α, via increasing peroxisome 
proliferator-activated receptor-gamma2 (PPARγ2) expression 
(64). On the hand, many of the inflammatory stimuli, such as
LPS, IL-1β and IL-6, have been shown to suppress adiponectin 
production in adipocytes (64-66).
Although CRP is predominantly produced from the liver tis-
sue, there is evidence suggesting that this protein is expressed 
in adipose tissue as well (67). Interestingly, mRNACRP level of 
white adipose tissue in adiponectin-deficient mice was higher
than that of wild-type mice, suggesting that adiponectin is a 
negative regulator of CRP expression. Indeed, an independent, 
inverse correlation between plasma levels of adiponectin and 
CRP has been reported in a large number of epidemiological 
studies (67,68). Increased levels of CRP and decreased levels 
of adiponectin are found in several obesity-related pathological 
conditions, such as T2DM and coronary heart disease. 
ATTENUATION OF ALLERGEN-INDUCED AIRWAY 
INFLAMMATION BY ADIPONECTIN 
Obesity is known to be an important risk factor for asthma, a 
complex disease characterized by airway inflammation (69).
Longitudinal studies indicate that obesity antedates asthma 
and that the relative risk of incident asthma increases with 
increasing obesity. A recent study by Shore et al suggested 
that adiponectin deficiency in obesity might contribute to the
pathogenesis of bronchial asthma (70). This study found that 
serum levels of adiponectin and its several putative recep-
tors (adipoR1, adipoR2, and T-cadherin) were significantly
decreased in a mouse model of ovalbumin (OVA)-induced 
pulmonary airway inflammation. Chronic treatment with
full-length adiponectin markedly attenuated the OVA-induced 
airway hyperresponsiveness to intravenous methacholine, and 
also significantly decreased OVA-induced increases of the
inflammatory cells in bronchoalveolar lavage fluid, includ-
ing macrophages, neutrophils, eosinophils and lymphocytes. 
Furthermore, adiponectin treatment prevented OVA-induced 
elevations of TH2 cytokines (IL-5 and IL-13) in bronchoal-
veolar lavage fluid. These novel findings further support the
anti-inflammatory activity of adiponectin, and also suggest a
role of adiponectin and/or its receptor agonists in the treat-
ment of asthma.
16
Biomed Rev 17, 2006
Cheng, Lam, Wang, and Xu 
ADIPOPHARMACOLOGY OF ADIPONECTIN
Enhanced adiponectin secretion  
by anti-inflammatory agents
Consistent with the role of adiponectin as an anti-inflammatory
adipokine, several drugs with anti-inflammatory properties
have been demonstrated to stimulate adiponectin secretion. 
These include (i) PPARγ agonists such as thiazolidinediones 
(TZDs) (71), (ii) angiotensin-converting enzyme inhibitors 
such as temocapril (72), (iii) angiotensin receptor blockers such 
as losartan, candesartan and telmisartan (73,74), (iv) inhibitors 
of NF-κB such as IMD-0354 (75), and (v) inhibitors of JNK 
such as SP600125 (22). 
 TZDs have been used as anti-diabetic drugs to improve 
systemic insulin sensitivity by enhancing glucose uptake in 
skeletal muscle and suppressing gluconeogenesis in liver tis-
sue (76). In addition, TZDs possess many other therapeutic 
benefits, such as alleviation of endothelial dysfunction and
carotid atherosclerosis (77), and amelioration of NAFLD and 
NASH (78). It is generally accepted that the therapeutic ben-
efits of TZDs on vascular disorders are partly attributed to its
anti-inflammatory actions, including (i) attenuation of TNF-α 
induced expression of adhesion molecules in endothelial cells 
(79), (ii) induction of cholesterol efflux and inhibition of in-
flammatory responses in macrophages (80), (iii) attenuation 
of NF-κB activation in smooth muscle cells (81), and (iv) 
suppression of TNF-α actions in adipocytes (82). In animal 
studies, TZDs treatment prevents monocyte/macrophage tar-
geting to atherosclerotic plaques in apolipoprotein E-deficient
mice (79). Clinical studies demonstrated that treatment with 
TZDs decreases a cluster of systemic inflammatory markers,
including CRP, IL-6, matrix metalloproteinase-9 (83,84), and 
plasminogen activator inhibitor 1 (85), independent of the 
improvement in insulin resistance. 
Many studies in both animal models and humans have dem-
onstrated that TZDs, such as rosiglitazone and pioglitazone, 
increase circulating levels of adiponectin, especially the HMW 
oligomeric form (71,86-88). The mechanism by which TZDs 
increase adiponectin production remains controversial. Iwaki 
et al (89) showed that TZDs could induce adiponectin mRNA 
expression by transactivating the adiponectin gene promoter 
through an PPAR-responsive element binding site. Likewise, 
a more recent report by Bodles et al (90) demonstrated that 
pioglitazone treatment selectively enhances the secretion of 
HMW adiponectin without affecting its mRNA levels in both 
human and mouse primary adipocytes. 
Two recent independent studies in adiponectin-deficient
mice suggested that the insulin-sensitizing effects of TZDs are 
at least in part dependent on their ability to induce adiponectin 
production (91,92). Nawrocki et al (92) showed that treatment 
of ob/ob mice with TZDs significantly increasedAMPK activ-
ity in both skeletal muscle and liver, and also improved glu-
cose tolerance, whereas these therapeutic effects were largely 
diminished in ob/ob mice lacking adiponectin. On the other 
hand, Kubota and colleagues (93) demonstrated that induction 
of adiponectin is required for the insulin-sensitizing activity 
of low-dose (10 mg/kg body weight), but not high-dose (30 
mg/kg body weight) pioglitazone in ob/ob mice. 
Pro-inflammatory actions of adiponectin
Although adiponectin is generally considered as an anti-inflam-
matory adipokine, there are also a number of studies demon-
strating that this adipokine might also exert pro-inflammatory
actions in certain situations. In human synovial fibroblasts,
adiponectin activates the p38 MAPK pathway, resulting in 
increased expression of IL-6 and matrix metalloproteinase-1, 
two important mediators of rheumatoid arthritis (94). These 
in vitro data are also supported by a clinical study showing 
that patients with rheumatoid arthritis have higher adiponectin 
levels in synovial fluid than those with osteoarthritis (95). In 
human colonic epithelial cell line HT-29, globular adiponectin 
has been shown to induce the expression of several pro-inflam-
matory cytokines, including IL-8, granulocyte macrophage 
colony stimulating factor and MCP-1, via activation of the 
ERK, p38 MAPK and NF-κB signaling cascades (96). An ex 
vivo study on human placenta and maternal adipose tissue also 
demonstrated that globular adiponectin could dose-depend-
ently increase the production of several pro-inflammatory
cytokines (IL1β, TNF-α and IL6) and prostaglandin 2, through 
inhibition of PPARγ and activation of the NF-κB and ERK1/2 
pathways (97). Furthermore, globular adiponectin has been 
shown to induce NF-κB activation in endothelial cells (98). 
The HMW oligomeric complex of adiponectin increases IL-6 
secretion in human monocytes (99), and activates NF-κB in 
myotubes, while the trimeric form of adiponectin lacks this 
activity (100). Therefore, the anti-inflammatory versus pro-
inflammatory functions of adiponectin may be dependent on its
target tissues or the oligomerization status of adiponectin. 
CONCLUSION AND PROSPECTIVE 
Although a number of recent studies have reported the pro-
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inflammatory activities of adiponectin under certain circum-
stances, the majority of data support the role of this adipokine 
as an anti-inflammatory agent, especially in the context of
obesity-associated inflammatory conditions (see Table). 
Adiponectin exerts its anti-inflammatory actions in multiple
targets by inhibiting the production and activities of TNF-α 
and other inflammatory molecules, attenuating the activation
of NF-κB and enhancing the expression of anti-inflammatory
cytokines. 
study by Mao et al (103) demonstrated the interaction between 
adiponectin receptors (adipoR1 and adipoR2) and APPL1, an 
intracellular protein containing pleckstrin homology domain, a 
phosphotyrosine binding domain and a leucine zippered coiled-
coil domain. Whether these putative receptors and APPL1 play 
a role in the inflammation-modulating activities of adiponectin
warrants further investigation. The detailed understanding of 
structural basis and cellular mechanisms underlying the anti-
inflammatory actions of adiponectin may provide useful infor-
mation for the future development of novel anti-inflammatory
therapies. Whether the inhibition of systemic inflammation and
the amelioration of obesity-related cardiometabolic disorders 
by TZDs and other drugs are indeed mediated by stimulation 
of adiponectin secretion and receptor-mediated activity need 
to be further pharmacologically investigated at both adipose 
and non-adipose tissue level. Note that adiponectin may also 
be produced by various nonfat cells such as cardiomyocytes, 
striated muscles, and hepatic stellate cells.
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